Abstracts by keywords: pricing regulation
In addition to other topics relevant to the pharmaceutical market, the law for greater security in the supply of pharmaceuticals (GSAV) in 2019 also stipulated regulations that affect the biosimilar market in the GKV. With the GSAV, certain new regulations have already been created and implemented, but additional changes are also promised after a period of three years. The latter relate not least to the planned interchangeability of biosimilars in pharmacies from 2022. Against this background, the authors of this article have published a scientific report, which is available as a full publication online under the “eFirst” section of the “Monitor Healthcare Research” (https: //www.monitor-sorgesforschung.de/efirst/Versorgung_Bios_2022/view), considerations were given as to which regulatory framework would do justice to the special market situation of biosimilars, particularly with regard to pricing (Bauer et al. 2021). The model developed in this context, which is intended as an alternative or counter-proposal to (partial/exclusive) discount contract tenders - which will be the logical consequence of the GSAV regulations - is presented below. This reimbursement and pricing model is intended to do justice to the market conditions analyzed in detail in the full publication in the sense of a sustainable competition concept in the biosimilar market and to be introduced into the health policy discussion.